We've found
184,457
clinical trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Other Clinical Trial
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Other Clinical Trial
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Other Clinical Trial
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Other Clinical Trial
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Other Clinical Trial
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Other Clinical Trial
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Psoriasis Clinical Trial
The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis.
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Nephrology / Urology Clinical Trial
Transfusion Trigger After Operations in High Cardiac Risk Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Nephrology / Urology Clinical Trial
Transfusion Trigger After Operations in High Cardiac Risk Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Nephrology / Urology Clinical Trial
Transfusion Trigger After Operations in High Cardiac Risk Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Nephrology / Urology Clinical Trial
Transfusion Trigger After Operations in High Cardiac Risk Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Esophageal Neoplasms Clinical Trial
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Esophageal Neoplasms Clinical Trial
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Esophageal Neoplasms Clinical Trial
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Esophageal Neoplasms Clinical Trial
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Adult Solid Tumor Clinical Trial
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Adult Solid Tumor Clinical Trial
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Adult Solid Tumor Clinical Trial
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Adult Solid Tumor Clinical Trial
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Huntington's Disease Clinical Trial
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Female Clinical Trial
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Phosphomannomutase 2 Deficiency Clinical Trial
Natural History Study Protocol in PMM2-CDG (CDG-Ia)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Epilepsy Clinical Trial
Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Epilepsy Clinical Trial
Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Epilepsy Clinical Trial
Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
We've found
184,457
clinical trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Clinical Trial
Updated: 12/31/1969
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Other Clinical Trial
Updated: 12/31/1969
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Other Clinical Trial
Updated: 12/31/1969
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Other Clinical Trial
Updated: 12/31/1969
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Other Clinical Trial
Updated: 12/31/1969
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Other Clinical Trial
Updated: 12/31/1969
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Other Clinical Trial
Updated: 12/31/1969
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Psoriasis Clinical Trial
Updated: 12/31/1969
The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis.
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Nephrology / Urology Clinical Trial
Updated: 12/31/1969
Transfusion Trigger After Operations in High Cardiac Risk Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Nephrology / Urology Clinical Trial
Updated: 12/31/1969
Transfusion Trigger After Operations in High Cardiac Risk Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Nephrology / Urology Clinical Trial
Updated: 12/31/1969
Transfusion Trigger After Operations in High Cardiac Risk Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cardiology / Vascular Diseases, Nephrology / Urology Clinical Trial
Updated: 12/31/1969
Transfusion Trigger After Operations in High Cardiac Risk Patients
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Esophageal Neoplasms Clinical Trial
Updated: 12/31/1969
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Esophageal Neoplasms Clinical Trial
Updated: 12/31/1969
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Esophageal Neoplasms Clinical Trial
Updated: 12/31/1969
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Esophageal Neoplasms Clinical Trial
Updated: 12/31/1969
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
Updated: 12/31/1969
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
Updated: 12/31/1969
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
Updated: 12/31/1969
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
Updated: 12/31/1969
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
Updated: 12/31/1969
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
Updated: 12/31/1969
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology Clinical Trial
Updated: 12/31/1969
A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Adult Solid Tumor Clinical Trial
Updated: 12/31/1969
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Adult Solid Tumor Clinical Trial
Updated: 12/31/1969
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Adult Solid Tumor Clinical Trial
Updated: 12/31/1969
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Adult Solid Tumor Clinical Trial
Updated: 12/31/1969
CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Huntington's Disease Clinical Trial
Updated: 12/31/1969
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Updated: 12/31/1969
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Updated: 12/31/1969
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Updated: 12/31/1969
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Updated: 12/31/1969
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Treatment Naive Follicular Lymphoma Clinical Trial
Updated: 12/31/1969
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Breast Cancer Female Clinical Trial
Updated: 12/31/1969
A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Updated: 12/31/1969
Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Immunology / Infectious Diseases Clinical Trial
Updated: 12/31/1969
Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Phosphomannomutase 2 Deficiency Clinical Trial
Updated: 12/31/1969
Natural History Study Protocol in PMM2-CDG (CDG-Ia)
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Epilepsy Clinical Trial
Updated: 12/31/1969
Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Epilepsy Clinical Trial
Updated: 12/31/1969
Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Epilepsy Clinical Trial
Updated: 12/31/1969
Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials